Tildrakizumab, an IL-12/p19 inhibitor, studied in 391 very active #PsA pts. Rx compared PBO vs 4 different doses and TIL showed superior ACR 20/50/70 responses (79.5%/52.6%/29.1% vs 24%PBO) and 80% PASI75 at wk24. #EULAR2019 LB0002 https://t.co/QKg0yDS28B